Stay updated on Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.

Latest updates to the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedTwo new study sites were added: Chongqing, China (400042) and Thane, India (411107). The list also shows removal/rename of Yuzhong District (Chongqing 400042) and Thāne (411107).SummaryDifference0.1%

- Check17 days agoChange Detected- Locations section updated with an expanded list of US states and Canadian provinces. - Page revision updated to v3.3.3; HHS Vulnerability Disclosure section removed.SummaryDifference0.7%

- Check24 days agoNo Change Detected
- Check38 days agoChange Detected- Revision: v3.3.2 is now displayed, replacing Revision: v3.3.1.SummaryDifference0.0%

- Check45 days agoChange DetectedAdded the labels 'Last Update Posted (Estimated)' and 'Revision: v3.3.1', and removed 'Last Update Posted' and 'Revision: v3.2.0'; this is a minor UI/versioning update that does not modify the study data or participation details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check52 days agoChange DetectedA new trial site was added: Tainan, Taiwan, 704, with a Last Update Posted entry on 2025-11-06. The prior listing for Tainan City, Taiwan, 704 was removed on 2025-10-28.SummaryDifference0.2%

- Check67 days agoChange DetectedRecent changes appear to be updates to study record dates (e.g., 2025-10-28, 2025-10-09, 2025-10) and do not alter core content such as design, eligibility, or endpoints. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.